Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hanmi Pharmaceutical Co. Ltd.

www.hanmipharm.com

Latest From Hanmi Pharmaceutical Co. Ltd.

KDDF’s Support Reflected In Robust R&D, Licensing By Korean Firms

Various government support schemes seem to have led to recent successful new drug development activities and licensing deals by South Korean pharma and biotech firms. The state-run Korea Drug Development Fund is seen as having played a key role in this effort, providing assistance to 153 R&D programs in the country so far to speed up development of novel and innovative global medicines.
Research & Development South Korea

Clinical Trial Data Highlight Korean Pharma’s R&D Shift Into Innovation

New clinical trial approval data show that early-stage studies of novel drug candidates by South Korean pharma and biotech firms sharply increased in 2018, underlining the industry’s ongoing shift towards innovation. Trials of oncology drugs continued to dominate, while clinical work in rare disorders such as hemophilia and Crohn’s disease has noticeably increased.

South Korea Clinical Trials

Lilly Sees New Product Gains, But Older Drugs Still Limit Growth Potential

Lilly noted strong growth for new products, but gains seen in the fourth quarter included older products with limited potential going forward. That puts even more pressure on the R&D pipeline and the company's revised guidance, but executives were optimistic about future growth drivers.

Sales & Earnings Business Strategies

Deal Watch: Purdue Continues Move Away From Opioids With Alivio Deal

In its continuing efforts to diversify away from opioid pain drugs, Purdue partners on non-opioid program with Alivio. Rigel licenses Tavalisse rights in all indications go to Spain’s Grifols.

Deals Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Gastrointestinal
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • South Korea
  • Parent & Subsidiaries
  • Hanmi Pharmaceutical Co. Ltd.
  • Senior Management
  • Gwan Sun Lee, PhD, Pres. & CEO
  • Contact Info
  • Hanmi Pharmaceutical Co. Ltd.
    Phone: 2 410 9114
    45, Bangi-dong
    Songpa-gu
    Seoul, 138-724
    South Korea
Advertisement
Advertisement
UsernamePublicRestriction

Register